Cenduit's Innovative IRT System Upgrade Provides User-Centric, Customizable Interface

Published on: 

Company News Release

Cenduit announces the delivery of its newly-designed IRT system interface

Cenduit, the largest Interactive Response Technology (IRT) specialist in the world, today announces the delivery of its newly-designed IRT system interface in response to feedback from clinical trial sites. The new IRT system upgrade provides a uniquely better and faster user experience, never available before.

Partnering with Smashing Boxes, a web and mobile app development company that specializes in usability and user experience, Cenduit’s refreshed IRT system breaks the mold for traditional systems by creating an intuitive, easy to use tablet- and mobile device-friendly interface. Specifically, it generates faster transactions; integrates a custom reporting tool; embeds role-specific user interfaces (rather than one size fits all); and provides 24/7 access to the global help desk through the web chat feature.


“Through several private and sponsored surveys, we asked a diverse group of IRT system users to tell us about their challenges and concerns with IRT systems. We heard them and tapped the remarkable talent of Smashing Boxes, who specializes in usability and the user experience, to incorporate this feedback into every aspect of our newly-designed, simple, customizable, intuitive, user-centric IRT system,” says Chris Dailey, Global Head of Technology at Cenduit. “We are confident that customers will be thrilled with these improvements – there’s nothing else like it today.”

For a product demo, click here to schedule a meeting with a Cenduit IRT specialist. Or visit Cenduit at any of the following trade shows for an in-person demo: Global Clinical Supplies Group European Conference, October 7-9, Barcelona, Spain; IRT 2014 Conference, October 20-21, Philadelphia, Pa.; DIA Japan 2014, November 16-18, Tokyo, Japan; Clinical Trial Supply Southern Calif., November 19-20, San Diego, Calif.; Outsourcing in Clinical Trials, February 3-4, 2015, Burlingame, Calif.